Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. - Wikidata - awgldk - TriplyDB

Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.

Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.

http://www.wikidata.org/entity/Q34487487

about

The Prevalence and Management of Systemic Amyloidosis in Western Countries Improved Cardiovascular Disease Outcomes in Older Adults Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).ECG low QRS voltage and wide QRS complex predictive of centenarian 360-day mortality Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.Advances in proteomic study of cardiac amyloidosis: progress and potential.Use of Noninvasive Imaging in Cardiac Amyloidosis.Recent Advances in Cardiovascular Imaging Relevant to the Management of Patients with Suspected Cardiac Amyloidosis.Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.Role of Imaging in Evaluating Infiltrative Heart Disease.Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.Imaging of Left Ventricular Hypertrophy: a Practical Utility for Differential Diagnosis and Assessment of Disease Severity.Amyloid Light-Chain Amyloidosis Manifesting as Heart Failure with Preserved Ejection Fraction in a Patient with Hyper-Immunoglobulin E-emia.Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.Congestive Heart Failure with Preserved Ejection Fraction in a Patient with Light Chain (AL) Amyloidosis and Multiple Myeloma.Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction.Impact of flow, gradient, and left ventricular function on outcomes after transcatheter aortic valve replacement.Impact of right ventricular distensibility on congestive heart failure with preserved left ventricular ejection fraction in the elderly.Transthyretin Cardiac Amyloidosis in Older Adults: Optimizing Cardiac Imaging to the Corresponding Diagnostic and Management Goal.Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis.Transthyretin cardiac amyloid and aortic stenosis in the elderly, the role of nuclear imaging.In search for novel functions of adenosine 5'-triphosphate (ATP) in the heart.Gender-related differences in heart failure with preserved ejection fraction.Prevalence of Cardiac Amyloidosis in Patients Referred for Transcatheter Aortic Valve Replacement.'A new staging system for cardiac transthyretin amyloidosis': is it already on the verge of obsolescence?Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.Special issues in heart failure: pulmonary hypertension, deranged potassium levels, and haemodynamic profiles.Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis.Heart rate in heart failure with preserved ejection fraction: target or marker?Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths.Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies.Diagnostic score for the detection of cardiac amyloidosis in patients with left ventricular hypertrophy and impact on prognosis Base-to-apex gradient pattern of cardiac impairment identified on myocardial T1 mapping in cardiac amyloidosis

P2860

Q26740436-063F6378-8146-4B39-9C60-DB83E8260933 Q26766094-EF351AC5-1C37-4BF8-B891-EE14A3F93EAB Q37083158-91656449-C110-4BE9-8399-00B9F1428DEA Q37219607-C248348A-25F4-44AB-BF6A-A5262AE57A91 Q38663987-62E48001-BB06-4AA9-90AA-8B65DC406E94 Q38807777-40EAA782-67AC-4586-86B9-744527E16DEB Q38809423-8C828382-94B3-4047-92A3-05C474BF3566 Q38834998-2E1445EB-246F-448A-B86E-32193FA83CDB Q38869625-D3B86B28-55A0-4A6E-BEBB-1DFAB13FA807 Q38939270-63D854C0-5BC9-425A-9877-754902369D7B Q39114674-596633CC-FB2B-4FE4-B41B-D6DB356CD1FC Q39217713-8D2B7FED-5AF2-4736-88B0-0C6ECFA4C540 Q39390119-2ECF1AF2-B004-44DE-853A-D0052E9E1FCC Q40084324-E10FF0C7-DE37-4079-90B3-7EC51FD38C69 Q40537439-7EFE0274-606F-4AB1-AD20-319AC775EC43 Q41072464-38620996-1A51-40E5-AA46-1CB7019B16AB Q41106725-BF31BAFE-8349-4ACE-9727-B5AB241693CC Q42695583-B8C88AFE-3545-4E84-BC47-A0E23C5A5C9A Q47255376-9E2F216A-5016-41CB-8F95-22639342D55F Q47637174-6815E1A3-0535-467F-8A09-94E43DC9C5EE Q47890686-12E03133-896D-4C5B-8715-790D1D8BD040 Q47987000-7A35841D-A116-4D87-A380-4348D668B771 Q48128152-77C5BD23-7D06-4631-8166-BCAB27409E8C Q48281128-ECDB9C07-889B-46CB-9A5B-112D1AF99917 Q48742311-EF39B3EF-79E5-4339-BF84-E1B25009B3E6 Q49342004-BFA0C089-399C-4FE0-9AA6-675566527AB0 Q49494490-68BF6D8D-7627-482F-9272-AF292143EAC9 Q49916288-73112F2D-BAC9-4782-926D-2084D8DA0E3B Q50093215-3BE1D588-648B-4E41-8518-9EDB04951EE3 Q50093236-D6EAA42E-BF0B-4C80-8FDE-7DDF978AC21C Q50132614-F75E382A-6747-4797-9E22-3798534335EF Q50167513-A749F0FD-7658-4E31-BA5D-2F0CBD44E01D Q50212765-00AD3940-F0DF-45D7-B3B4-7A356017C3CB Q55425790-EB4C7776-A62E-4CC4-B7FD-06FB2A2EB8B0 Q58252419-959303E5-9EBE-466B-9863-410D9EF0847F Q58602803-9B0AD6D8-4ED6-4883-AF03-35C13EB34E89

P2860

Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.

http://www.wikidata.org/entity/Q34487487

description

2015 nî lūn-bûn

@nan

2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Wild-type transthyretin amyloi ...... h preserved ejection fraction.

@ast

Wild-type transthyretin amyloi ...... h preserved ejection fraction.

@en

Wild-type transthyretin amyloi ...... h preserved ejection fraction.

@nl

type

label

Wild-type transthyretin amyloi ...... h preserved ejection fraction.

@ast

Wild-type transthyretin amyloi ...... h preserved ejection fraction.

@en

Wild-type transthyretin amyloi ...... h preserved ejection fraction.

@nl

prefLabel

Wild-type transthyretin amyloi ...... h preserved ejection fraction.

@ast

Wild-type transthyretin amyloi ...... h preserved ejection fraction.

@en

Wild-type transthyretin amyloi ...... h preserved ejection fraction.

@nl

P1433

Q34487487-08E3478D-572B-449E-8561-CB6FBE1BCD04

P1476

Q34487487-39E1D578-AC88-42E9-87CB-D06AFA778A55

P2093

Q34487487-0796CDE2-BE6C-410D-A8ED-F43749427EBF

Q34487487-68380B1D-C2BE-4A4E-B13B-BD48D9644A5D

Q34487487-6DE5811A-C6A5-4056-BA3D-D46EF416801F

Q34487487-C027568B-8616-4B3E-AC22-6DD09E4CD7F1

Q34487487-CD5D5E94-41F7-4830-8CA2-A67BA56AF408

Q34487487-D03FFFE9-EC43-497C-93CF-2306E6B8F9E4

Q34487487-E43BA455-F6EC-4ACA-90D9-8ED1BBCBAC2D

Q34487487-ED108A0F-75FF-486A-B581-7A9833B32439

Q34487487-FFDDC276-10E1-4774-90DE-7EDEA07BF2BE

P2860

Q34487487-0660FBF6-33A8-43EA-8896-12E53020A32E

Q34487487-0CDD29A1-EF2D-44AF-B5B3-982CC06031CA

Q34487487-0FAE941D-D505-49E1-9C9B-3DF3E2B9FADD

Q34487487-11DD5B0C-099F-459B-8555-4AC775BAF41A

Q34487487-183F0AA8-2E37-4ABC-ADDC-F3A1985A39E0

Q34487487-18F3E509-296E-450E-B1F4-C257FBFE243E

Q34487487-22869843-037E-467B-A3A3-FD39FF615F86

Q34487487-236A07FC-D284-409B-B43E-BAEACEE0989E

Q34487487-24D85C58-778C-4977-9FA7-499F1AE110F1

Q34487487-24FAFFE9-D3B5-4818-9A60-CCD7C04367C9

P304

Q34487487-55FF1699-3951-4062-9F40-C02300005AD7

P31

Q34487487-3490114D-08F3-4AEF-A9C6-D28D47621B6B

P356

Q34487487-6275C6EC-01FF-4A5B-BC21-53613F6A1BE6

P433

Q34487487-2845F5F9-B21B-4156-9626-36F3733013C0

P478

Q34487487-78917150-390A-4BD3-A9A5-F4E7A3A76662

P50

Q34487487-2AEAD2BD-BC23-4F58-B53A-E4BEC2133165

Q34487487-3F9AE208-C6D5-42CF-9E62-A942D959C7A5

P577

Q34487487-44E018A8-0A23-436D-9E54-A49729B4C611

P5875

Q34487487-EA1BF9A4-DFDD-451C-8AF3-9DB8F8CE74AB

P698

Q34487487-CB63EB42-275F-4061-8854-8C8139CD755C

P921

Q34487487-1BAE56A5-6260-4B3B-BF8A-826BBAB0186D

P356

P1433

European Heart Journal

P1476

Wild-type transthyretin amyloi ...... h preserved ejection fraction.

@en

P2093

Belén Bornstein

http://www.w3.org/2001/XMLSchema#string

Carolina Robles

http://www.w3.org/2001/XMLSchema#string

Clara Salas

http://www.w3.org/2001/XMLSchema#string

Esther González-López

http://www.w3.org/2001/XMLSchema#string

F Javier de Haro-Del Moral

http://www.w3.org/2001/XMLSchema#string

Gonzalo Guzzo-Merello

http://www.w3.org/2001/XMLSchema#string

Luis Alonso-Pulpon

http://www.w3.org/2001/XMLSchema#string

Marta Cobo-Marcos

http://www.w3.org/2001/XMLSchema#string

Pablo Garcia-Pavia

http://www.w3.org/2001/XMLSchema#string

P2860

A new equation to estimate glomerular filtration rate

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.

Developing therapies for heart failure with preserved ejection fraction: current state and future directions

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

Senile systemic amyloidosis: clinical features at presentation and outcome.

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.

Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.

Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

P304

2585-2594

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHV338

http://www.w3.org/2001/XMLSchema#string

P433

38

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Enrique Lara-Pezzi

Maria Gallego-Delgado

P577

2015-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280585370

http://www.w3.org/2001/XMLSchema#string

P698

26224076

http://www.w3.org/2001/XMLSchema#string

P921